Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies
Top Cited Papers
- 15 November 2002
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (22), 4420-4427
- https://doi.org/10.1200/jco.2002.01.133
Abstract
PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies.Keywords
This publication has 20 references indexed in Scilit:
- Antigen processing by the proteasomeNature Reviews Molecular Cell Biology, 2001
- The Ubiquitin-Dependent Proteolytic System and other Potential Targets for the Modulation of Nuclear Factor-kB (NF-kB)Current Drug Targets, 2000
- Catalytic Activities of the 20 S Proteasome, a Multicatalytic Proteinase ComplexArchives of Biochemistry and Biophysics, 2000
- Ubiquitin-mediated proteolysis: biological regulation via destructionBioEssays, 2000
- Dis-assembly lines: the proteasome and related ATPase-assisted proteases.Current Opinion in Structural Biology, 2000
- The role of the ubiquitin-proteasome pathway in apoptosisCell Death & Differentiation, 1999
- Apoptosis and the ProteasomePublished by Springer Science and Business Media LLC ,1999
- The Proteasome Is Involved in AngiogenesisBiochemical and Biophysical Research Communications, 1998
- Roles of ubiquitin-mediated proteolysis in cell cycle controlCurrent Opinion in Cell Biology, 1997
- Lactacystin, a Specific Inhibitor of the Proteasome, Induces Apoptosis in Human Monoblast U937 CellsBiochemical and Biophysical Research Communications, 1995